07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Genetic Immunity, Power of the Dream Ventures deal

Technology holding company Power of the Dream acquired nanomedicines company Genetic Immunity. Genetic Immunity is developing the DermaVir Patch to treat HIV infection. The synthetic plasmid DNA-containing vaccine administered topically by the dendritic cell-targeting DermaPrep...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Genetic Immunity infectious news

Genetic Immunity joined the West Nile Integrated Shield Project, a three-year project to develop a vaccine for West Nile virus (WNV) funded by the European Commission's Directorate-General for Research and Innovation. Genetic Immunity will use...
07:00 , Jul 26, 2010 |  BC Week In Review  |  Clinical News

DermaVir Patch: Phase II data

In a double-blind, dose-ranging, German Phase II trial in 36 treatment-naïve HIV patients, 4 topical patches of DermaVir containing 0.1 mg DNA per patch administered every 6 weeks for 18 weeks significantly reduced HIV viral...
23:48 , Jul 19, 2010 |  BC Extra  |  Clinical News

Genetic Immunity, Virostatics report HIV data

Genetic Immunity LLC (McLean, Va.) and Virostatics s.r.l. (Sassari, Italy) both reported HIV data at the International AIDS Conference in Vienna. Genetic Immunity's DermaVir Patch significantly reduced HIV viral load from baseline to week 24...
07:00 , Apr 27, 2009 |  BC Week In Review  |  Clinical News

DermaVir Patch: Phase II started

Genetic Immunity began a single-blind, placebo-controlled, Italian Phase II trial (PHPC-02) to evaluate 1 application of DermaVir Patch every month for 3 months in 16 patients undergoing highly active antiretroviral therapy (HAART). Genetic Immunity LLC...
08:00 , Nov 24, 2008 |  BC Week In Review  |  Clinical News

DermaVir Patch: Phase II started

Genetic Immunity began a placebo-controlled, German Phase II trial to evaluate 2, 4, or 8 DermaVir Patches of 0.1 mg DNA per patch every 6 weeks for 18 weeks in 36 treatment-naïve HIV-1 infected patients....
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

DermaVir Patch: Phase I/II data

In a Hungarian Phase I/II study (GIHU004) in 9 HIV patients on HAART, the DermaVir Patch induced HIV-specific immune responses. Patients had significant increases in PHPC counts and long-lasting precursor T cell responses. There were...